AstraZeneca, E.Digital, ‘Papples’: Intellectual Property

April 3 (Bloomberg) -- AstraZeneca Plc, the U.K.’s second-biggest drugmaker, said it may appeal a U.S. court ruling that invalidated a patent on its Pulmicort Respules asthma treatment and cleared the way for generic competition.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.